Endocrinology status update: Difference between revisions
Jump to navigation
Jump to search
Line 431: | Line 431: | ||
|- | |- | ||
|} | |} | ||
==Completed chapters== | ==Completed chapters== | ||
Line 670: | Line 445: | ||
|- | |- | ||
| rowspan="88" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |CVS | | rowspan="88" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold;" |CVS | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Diabetes Landing Page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | | style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | ||
Line 678: | Line 453: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Diabetes Type I | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | | style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | ||
Line 686: | Line 461: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Diabetes Type II | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sahar | | style="padding: 5px 5px; background: #F5F5F5;" |Sahar | ||
Line 726: | Line 501: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Hasan | | style="padding: 5px 5px; background: #F5F5F5;" |Hasan | ||
Line 734: | Line 509: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ifeoma | | style="padding: 5px 5px; background: #F5F5F5;" |Ifeoma | ||
Line 742: | Line 517: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Beri Beri | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
Line 750: | Line 525: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Shadi Ebr | | style="padding: 5px 5px; background: #F5F5F5;" |Shadi Ebr | ||
Line 758: | Line 533: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Hypogonadism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Usman Ali Akbar | | style="padding: 5px 5px; background: #F5F5F5;" |Usman Ali Akbar | ||
Line 766: | Line 541: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |GH deficiency | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sogand | | style="padding: 5px 5px; background: #F5F5F5;" |Sogand | ||
Line 774: | Line 549: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Prolactinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | | style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | ||
Line 782: | Line 557: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Acromegaly | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | | style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | ||
Line 790: | Line 565: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Pituitary apoplexy | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | | style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | ||
Line 798: | Line 573: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroid disorders landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Niloofar | | style="padding: 5px 5px; background: #F5F5F5;" |Niloofar | ||
Line 806: | Line 581: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Hyperthyroidism landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ali | | style="padding: 5px 5px; background: #F5F5F5;" |Ali | ||
Line 814: | Line 589: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Graves Disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ifrah Fatima | | style="padding: 5px 5px; background: #F5F5F5;" |Ifrah Fatima | ||
Line 822: | Line 597: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Goiter | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Huda | | style="padding: 5px 5px; background: #F5F5F5;" |Huda | ||
Line 830: | Line 605: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Toxic Multinodular goiter | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sogand | | style="padding: 5px 5px; background: #F5F5F5;" |Sogand | ||
Line 838: | Line 613: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Toxic adenoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Huda | | style="padding: 5px 5px; background: #F5F5F5;" |Huda | ||
Line 846: | Line 621: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Struma ovarii | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fahime | | style="padding: 5px 5px; background: #F5F5F5;" |Fahime | ||
Line 854: | Line 629: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Hypothyroidism landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
Line 862: | Line 637: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Primary hypothyroidism (hypothyroidism) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | | style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | ||
Line 870: | Line 645: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Hashimoto thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
Line 886: | Line 661: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Secondary hypothyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fahime | | style="padding: 5px 5px; background: #F5F5F5;" |Fahime | ||
Line 894: | Line 669: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroiditis Landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
Line 902: | Line 677: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Hashimotos Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed | | style="padding: 5px 5px; background: #F5F5F5;" |Ahmed | ||
Line 910: | Line 685: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | style="padding: 5px 5px; background: #F5F5F5;" |Dequervian Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Hasan | | style="padding: 5px 5px; background: #F5F5F5;" |Hasan | ||
Line 918: | Line 693: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Riedel's Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | | style="padding: 5px 5px; background: #F5F5F5;" |Sabawoon | ||
Line 926: | Line 701: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Silent Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | | style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | ||
Line 934: | Line 709: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Postpartum Thyroiditis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Apeksha Gupta | | style="padding: 5px 5px; background: #F5F5F5;" |Apeksha Gupta | ||
Line 942: | Line 717: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroid nodule | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush | | style="padding: 5px 5px; background: #F5F5F5;" |Soroush | ||
Line 950: | Line 725: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Sick euthyroid syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fahime | | style="padding: 5px 5px; background: #F5F5F5;" |Fahime | ||
Line 958: | Line 733: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Thyroid carcinoma landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna | | style="padding: 5px 5px; background: #F5F5F5;" |Krishna | ||
Line 966: | Line 741: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Myxedama coma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sara | | style="padding: 5px 5px; background: #F5F5F5;" |Sara | ||
Line 974: | Line 749: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Postpartum thyroid dysfunction L. | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna | | style="padding: 5px 5px; background: #F5F5F5;" |Krishna | ||
Line 982: | Line 757: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Adrenal disorders landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush | | style="padding: 5px 5px; background: #F5F5F5;" |Soroush | ||
Line 990: | Line 765: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Adrenal insufficiency landing page | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Aditya | | style="padding: 5px 5px; background: #F5F5F5;" |Aditya | ||
Line 998: | Line 773: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Adrenocortical carcinoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ali | | style="padding: 5px 5px; background: #F5F5F5;" |Ali | ||
Line 1,006: | Line 781: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |CAH L | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Homa | | style="padding: 5px 5px; background: #F5F5F5;" |Homa | ||
Line 1,014: | Line 789: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |21 hydroxylase def | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sogand | | style="padding: 5px 5px; background: #F5F5F5;" |Sogand | ||
Line 1,022: | Line 797: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |11 hydroxylase def | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
Line 1,030: | Line 805: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |17 hydroxylase def | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Homa | | style="padding: 5px 5px; background: #F5F5F5;" |Homa | ||
Line 1,038: | Line 813: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Addisons disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Soroush | | style="padding: 5px 5px; background: #F5F5F5;" |Soroush | ||
Line 1,046: | Line 821: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Incidentiloma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Anahita Deylamshahi | | style="padding: 5px 5px; background: #F5F5F5;" |Anahita Deylamshahi | ||
Line 1,054: | Line 829: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Pheochromocytoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Mohammed Salih | | style="padding: 5px 5px; background: #F5F5F5;" |Mohammed Salih | ||
Line 1,062: | Line 837: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |P hyperaldosteronism(Conn's) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Akash Daswaney | | style="padding: 5px 5px; background: #F5F5F5;" |Akash Daswaney | ||
Line 1,070: | Line 845: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hypoaldosteronism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | | style="padding: 5px 5px; background: #F5F5F5;" |Ramyar | ||
Line 1,078: | Line 853: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Cushing's syndrome/Pseudo-Cushing's syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ifoma | | style="padding: 5px 5px; background: #F5F5F5;" |Ifoma | ||
Line 1,086: | Line 861: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Secondary Adrenal Insufficiency | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sahar | | style="padding: 5px 5px; background: #F5F5F5;" |Sahar | ||
Line 1,094: | Line 869: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |'''MEN type I''' | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdulkareem Lukan | | style="padding: 5px 5px; background: #F5F5F5;" |Abdulkareem Lukan | ||
Line 1,102: | Line 877: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |MEN type 2 | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
Line 1,110: | Line 885: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Protein energy maln. (Kwashiorkor, Marasmus) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ibtisam Ashraf | | style="padding: 5px 5px; background: #F5F5F5;" |Ibtisam Ashraf | ||
Line 1,118: | Line 893: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Metabolic syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Mandana | | style="padding: 5px 5px; background: #F5F5F5;" |Mandana | ||
Line 1,126: | Line 901: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hypoglycemia | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Niloofar | | style="padding: 5px 5px; background: #F5F5F5;" |Niloofar | ||
Line 1,134: | Line 909: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Glucaganoma | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Homa | | style="padding: 5px 5px; background: #F5F5F5;" |Homa | ||
Line 1,142: | Line 917: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Insulinoma (hyperinsulism, hyperinsulinemia) | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Shivam | | style="padding: 5px 5px; background: #F5F5F5;" |Shivam | ||
Line 1,150: | Line 925: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |DKA | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Amandeep | | style="padding: 5px 5px; background: #F5F5F5;" |Amandeep | ||
Line 1,158: | Line 933: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |HONK/HHS | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Amandeep | | style="padding: 5px 5px; background: #F5F5F5;" |Amandeep | ||
Line 1,166: | Line 941: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Androgen insensitivity | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | | style="padding: 5px 5px; background: #F5F5F5;" |Maneesha | ||
Line 1,174: | Line 949: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Gynecomastia | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Huda | | style="padding: 5px 5px; background: #F5F5F5;" |Huda | ||
Line 1,182: | Line 957: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hirsutism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Ahmed | | style="padding: 5px 5px; background: #F5F5F5;" |Ahmed | ||
Line 1,190: | Line 965: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Polycystic Ovarian Disease | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sahar | | style="padding: 5px 5px; background: #F5F5F5;" |Sahar | ||
Line 1,198: | Line 973: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Delayed puberty | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | | style="padding: 5px 5px; background: #F5F5F5;" |Abdelrahman | ||
Line 1,206: | Line 981: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Parathyroid disorders LP | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fahime | | style="padding: 5px 5px; background: #F5F5F5;" |Fahime | ||
Line 1,214: | Line 989: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hypoparathyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Qasim Khurshid | | style="padding: 5px 5px; background: #F5F5F5;" |Qasim Khurshid | ||
Line 1,222: | Line 997: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Pseudohypoparathyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Shakiba Hassanzadeh | | style="padding: 5px 5px; background: #F5F5F5;" |Shakiba Hassanzadeh | ||
Line 1,230: | Line 1,005: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Hyperparathyroidism | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Aditya | | style="padding: 5px 5px; background: #F5F5F5;" |Aditya | ||
Line 1,238: | Line 1,013: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Familial hypocalciuric hypercalcemia | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sara Zand | | style="padding: 5px 5px; background: #F5F5F5;" |Sara Zand | ||
Line 1,246: | Line 1,021: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Osteoporosis | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna | | style="padding: 5px 5px; background: #F5F5F5;" |Krishna | ||
Line 1,254: | Line 1,029: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Zollinger-Ellison syndrome | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Krishna | | style="padding: 5px 5px; background: #F5F5F5;" |Krishna | ||
Line 1,262: | Line 1,037: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Syndrome of inappropriate antidiuretic hormone | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Fahime | | style="padding: 5px 5px; background: #F5F5F5;" |Fahime | ||
Line 1,270: | Line 1,045: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Autoimmune polyendocrine syndromes | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Huda | | style="padding: 5px 5px; background: #F5F5F5;" |Huda | ||
Line 1,278: | Line 1,053: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" |Amenorrhea | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Assigned | | style="padding: 5px 5px; background: #F5F5F5;" |Assigned | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Sahar | | style="padding: 5px 5px; background: #F5F5F5;" |Sahar | ||
Line 1,286: | Line 1,061: | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | | style="padding: 5px 5px; background: #F5F5F5;" | | ||
|- | |- | ||
|} | |} |
Revision as of 03:14, 22 July 2020
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Huda A. Karman, M.D.
System leader: Sogand Goudarzi, M.D.
Progress | |
---|---|
Completed | |
In progress | |
Remaining |
List of Chapters Requiring Content
Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
---|---|---|---|---|---|---|---|
Endocrinology | Pheochromocytoma | Assigned | Ifrah | Sogand | In Progress | ||
Metabolic syndrome X | Assigned | Mina | Sogand | In Progress | |||
Gestentional Diabetes | |||||||
Disbetes Insipidus | Assigned | Anahita | Krishna | In Progress | |||
Hypopitutarism | |||||||
Sheenhan's Syndrome | |||||||
Hypogonadism | |||||||
GH deficiency | |||||||
Primary hyperaldostronism | |||||||
In progress chapters
Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
---|---|---|---|---|---|---|---|
Endocrinology | Metabolic syndrome X | Assigned | Fatemeh Dehghani Fiouzabadi | Sogand | In progress | Sogand | |
DM Type I | Assigned | Sogand | In progress | ||||
Disbetes Insipidus | Assigned | Anahita | Krishna | In progress | |||
Completed chapters
Category | Chapters that need content | Assignment Status | Scholar's name | Coach name | Completion Status | Review status | Reviewer name |
---|---|---|---|---|---|---|---|
CVS | Diabetes Landing Page | Assigned | Ramyar | Complete | In progress | ||
Diabetes Type I | Assigned | Sabawoon | Complete | In progress | |||
Diabetes Type II | Assigned | Sahar | Complete | In progress | |||
Diabetes insipidus | Assigned | Sahar | Complete | In progress | |||
Pituitary disorders landing page | Assigned | Cafer Zorkon | Complete | In progress | |||
Hypopituitarism | Assigned | Mandana | Complete | In progress | |||
Sheehan Syndrome | Assigned | Javaria Anwer | Farima | Complete | In progress | ||
Assigned | Hasan | Complete | In progress | ||||
Assigned | Ifeoma | Complete | In progress | ||||
Beri Beri | Assigned | Abdelrahman | Complete | In progress | |||
Assigned | Shadi Ebr | Sahar | Complete | In progress | |||
Hypogonadism | Assigned | Usman Ali Akbar | Sara | Complete | In progress | ||
GH deficiency | Assigned | Sogand | Complete | In progress | |||
Prolactinoma | Assigned | Maneesha | Complete | In progress | |||
Acromegaly | Assigned | Sabawoon | Complete | In progress | |||
Pituitary apoplexy | Assigned | Ramyar | Complete | In progress | |||
Thyroid disorders landing page | Assigned | Niloofar | Complete | In progress | |||
Hyperthyroidism landing page | Assigned | Ali | Complete | In progress | |||
Graves Disease | Assigned | Ifrah Fatima | Sogand | Complete | In progress | ||
Goiter | Assigned | Huda | Complete | In progress | |||
Toxic Multinodular goiter | Assigned | Sogand | Complete | In progress | |||
Toxic adenoma | Assigned | Huda | Complete | In progress | |||
Struma ovarii | Assigned | Fahime | Complete | In progress | |||
Hypothyroidism landing page | Assigned | Abdelrahman | Complete | In progress | |||
Primary hypothyroidism (hypothyroidism) | Assigned | Maneesha | Complete | In progress | |||
Hashimoto thyroiditis | Assigned | Abdelrahman | Complete | In progress | |||
Congenital hypothyroidism/Cretinism | Assigned | Aditya | Complete | In progress | |||
Secondary hypothyroidism | Assigned | Fahime | Complete | In progress | |||
Thyroiditis Landing page | Assigned | Abdelrahman | Complete | In progress | |||
Hashimotos Thyroiditis | Assigned | Ahmed | Complete | In progress | |||
Dequervian Thyroiditis | Assigned | Hasan | Complete | In progress | |||
Riedel's Thyroiditis | Assigned | Sabawoon | Complete | In progress | |||
Silent Thyroiditis | Assigned | Ramyar | Complete | In progress | |||
Postpartum Thyroiditis | Assigned | Apeksha Gupta | Aditya | Complete | In progress | ||
Thyroid nodule | Assigned | Soroush | Complete | In progress | |||
Sick euthyroid syndrome | Assigned | Fahime | Complete | In progress | |||
Thyroid carcinoma landing page | Assigned | Krishna | Complete | In progress | |||
Myxedama coma | Assigned | Sara | Complete | In progress | |||
Postpartum thyroid dysfunction L. | Assigned | Krishna | Complete | In progress | |||
Adrenal disorders landing page | Assigned | Soroush | Complete | In progress | |||
Adrenal insufficiency landing page | Assigned | Aditya | Complete | In progress | |||
Adrenocortical carcinoma | Assigned | Ali | Complete | In progress | |||
CAH L | Assigned | Homa | Complete | In progress | |||
21 hydroxylase def | Assigned | Sogand | Complete | In progress | |||
11 hydroxylase def | Assigned | Ali | Complete | In progress | |||
17 hydroxylase def | Assigned | Homa | Complete | In progress | |||
Addisons disease | Assigned | Soroush | Complete | In progress | |||
Incidentiloma | Assigned | Anahita Deylamshahi | Krishna | Complete | In progress | ||
Pheochromocytoma | Assigned | Mohammed Salih | Complete | In progress | |||
P hyperaldosteronism(Conn's) | Assigned | Akash Daswaney | Homa | Complete | In progress | ||
Hypoaldosteronism | Assigned | Ramyar | Complete | In progress | |||
Cushing's syndrome/Pseudo-Cushing's syndrome | Assigned | Ifoma | Complete | In progress | |||
Secondary Adrenal Insufficiency | Assigned | Sahar | Complete | In progress | |||
MEN type I | Assigned | Abdulkareem Lukan | Sahar | Complete | In progress | ||
MEN type 2 | Assigned | Abdelrahman | Complete | In progress | |||
Protein energy maln. (Kwashiorkor, Marasmus) | Assigned | Ibtisam Ashraf | Sahar | Complete | In progress | ||
Metabolic syndrome | Assigned | Mandana | Complete | In progress | |||
Hypoglycemia | Assigned | Niloofar | Complete | In progress | |||
Glucaganoma | Assigned | Homa | Complete | In progress | |||
Insulinoma (hyperinsulism, hyperinsulinemia) | Assigned | Shivam | Sara | Complete | In progress | ||
DKA | Assigned | Amandeep | Complete | In progress | |||
HONK/HHS | Assigned | Amandeep | Complete | In progress | |||
Androgen insensitivity | Assigned | Maneesha | Complete | In progress | |||
Gynecomastia | Assigned | Huda | Complete | In progress | |||
Hirsutism | Assigned | Ahmed | Complete | In progress | |||
Polycystic Ovarian Disease | Assigned | Sahar | Complete | In progress | |||
Delayed puberty | Assigned | Abdelrahman | Complete | In progress | |||
Parathyroid disorders LP | Assigned | Fahime | Complete | In progress | |||
Hypoparathyroidism | Assigned | Qasim Khurshid | Maneesha | Complete | In progress | ||
Pseudohypoparathyroidism | Assigned | Shakiba Hassanzadeh | Ahmed | Complete | In progress | ||
Hyperparathyroidism | Assigned | Aditya | Complete | In progress | |||
Familial hypocalciuric hypercalcemia | Assigned | Sara Zand | Fahime | Complete | In progress | ||
Osteoporosis | Assigned | Krishna | Complete | In progress | |||
Zollinger-Ellison syndrome | Assigned | Krishna | Complete | In progress | |||
Syndrome of inappropriate antidiuretic hormone | Assigned | Fahime | Complete | In progress | |||
Autoimmune polyendocrine syndromes | Assigned | Huda | Complete | In progress | |||
Amenorrhea | Assigned | Sahar | Complete | In progress | |||